Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Nanomedicine 2013

Frederic Lagarce's Biography



Frederic Lagarce, Professor, University of Angers

Pr. Frederic Lagarce is a Pharmacist educated in the Universities of Paris XI and Angers in France. In the latter University he achieved a specialization in Hospital Pharmacy during 4 years and a 3 year PhD program. Since 2005, he has been working as a Hospital Pharmacist and was nominated assistant professor in 2008 and Professor of biopharmaceutics & Pharmaceutical technology in 2012. He started is research in 1999 in the lab of Pr. Jean-Pierre Benoit on microparticles . In the mid 2000’s he started to lead research programs on lipid nanocapsules for the oral and the pulmonary route mainly in the field of cancer therapy. Frederic Lagarce focuses his research on Bioavailability enhancement by playing on the interactions between the drug products (mainly nanosystems) and the living tissues. This field involves biological barrier crossing studies but also stability assessment of the active moieties and the formulation in vivo. The research area is thus at the frontiers of physiology, molecular biology, physical chemistry and pharmaceutical technology. Because of his position at the hospital, Frederic Lagarce is in strong interaction with the medical staff and this has an important influence on his translational research which can be shortened as “finding new answers to medical needs using innovative drug formulations”.

Frederic Lagarce Image

Lipid Nanocapsules for the Oral Delivery of Fragile or Poorly Soluble Compounds

Friday, 12 April 2013 at 09:00

Add to Calendar ▼2013-04-12 09:00:002013-04-12 10:00:00Europe/LondonLipid Nanocapsules for the Oral Delivery of Fragile or Poorly Soluble CompoundsNanomedicine 2013 in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com

Oral delivery is the first choice route of administration that allow a good compliance, safety and ambulatory therapy. Unfortunately the bioavailability of poorly soluble or fragile compounds is not good after oral administration. Lipid Nanocapsules (LNCs) while protecting the drug and enhancing its permeability across epithelial digestive barrier can be a solution to allow oral administration of first line therapies such as paclitaxel (lung and breast cancer) or fondaparinux (anticoagulant). The devellopement and characterisation of LNCs and their mechanisms of uptake across the intestinal barriers will be presented.


Add to Calendar ▼2013-04-11 00:00:002013-04-12 00:00:00Europe/LondonNanomedicine 2013Nanomedicine 2013 in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com